MD Inman and PM O'Byrne
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Pretreatment with inhaled beta 2-agonists is often recommended for the prevention of exercise-induced bronchoconstriction. Regular treatment with inhaled beta 2-agonists has been associated with worsened baseline airway caliber and increased airway responsiveness. In this study, we have investigated the effects of regular inhaled albuterol on the severity of exercise-induced bronchoconstriction using a double-blind, placebo-controlled, randomized, crossover design. Ten subjects inhaled either albuterol or placebo (2 x 100 micrograms, four times per day) for 7 d. On the eighth and ninth days of treatment periods, subjects performed 5-min constant work rate cycle ergometry exercise challenges after inhaling 200 micrograms of placebo (eighth day) or albuterol (ninth day). Forced expired volume in 1 s (FEV1) was measured on arrival in the laboratory as well as before and for 1 h after exercise. One week of regular inhaled albuterol compared with placebo resulted in: (1) a lower baseline FEV1 (mean difference, 230 ml) (p = 0.02); (2) a lower minimum postexercises FEV1 without inhaled albuterol pretreatment (mean difference, 390 ml; range, -50 ml to 1,250 ml) (p = 0.01); (3) a lower minimum postexercise FEV1 with inhaled albuterol pretreatment (p < 0.01). The smallest degree of exercise-induced bronchoconstriction occurred after a week of regular placebo and pretreatment with inhaled albuterol immediately before exercise. Inhalation of albuterol four times daily for 1 wk worsens exercise- induced bronchoconstriction; however, it remains extremely effective when used immediately before exercise for preventing bronchoconstriction.

This article has been cited by other articles:

				M. Cazzola and M. G. Matera Review: Safety of long-acting {beta}2 -agonists in the treatment of asthma Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 35 - 46. [Abstract] [PDF]

				J. Chavez, P. Segura, M. H. Vargas, J. L. Arreola, E. Flores-Soto, and L. M. Montano Paradoxical effect of salbutamol in a model of acute organophosphates intoxication in guinea pigs: role of substance P release Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L915 - L923. [Abstract] [Full Text] [PDF]

				A Bruton and M Thomas Breathing therapies and bronchodilator use in asthma. Thorax, August 1, 2006; 61(8): 643 - 645. [Full Text] [PDF]

				M. Miyamoto, M. Tomaki, J. Lotvall, and A. Linden {beta}-Adrenoceptor stimulation and neutrophil accumulation in mouse airways Eur. Respir. J., August 1, 2004; 24(2): 231 - 237. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Respiratory Tolerance to Regular {beta}2-Agonist Use in Patients with Asthma Ann Intern Med, May 18, 2004; 140(10): 802 - 813. [Abstract] [Full Text] [PDF]

				A. Pfleger, E. Eber, E. Weinhandl, and M.S. Zach Effects of nedocromil and salbutamol on airway reactivity in children with asthma Eur. Respir. J., September 1, 2002; 20(3): 624 - 629. [Abstract] [Full Text] [PDF]

				R. J. Hancox, P. Subbarao, D. Kamada, R. M. Watson, F. E. Hargreave, and M. D. Inman beta 2-Agonist Tolerance and Exercise-induced Bronchospasm Am. J. Respir. Crit. Care Med., April 15, 2002; 165(8): 1068 - 1070. [Abstract] [Full Text] [PDF]

				B. Dahlen, P.M. O'Byrne, R.M. Watson, A. Roquet, F. Larsen, and M.D. Inman The reproducibility and sample size requirements of exercise-induced bronchoconstriction measurements Eur. Respir. J., April 1, 2001; 17(4): 581 - 588. [Abstract] [Full Text] [PDF]

				R. Jokic, V. A. Swystun, B. E. Davis, and D. W. Cockcroft Regular Inhaled Salbutamol : Effect on Airway Responsiveness to Methacholine and Adenosine 5'-Monophosphate and Tolerance to Bronchoprotection Chest, February 1, 2001; 119(2): 370 - 375. [Abstract] [Full Text] [PDF]

				Y. Y. Koh, Y. Park, J. H. Jeong, C. K. Kim, Y.-G. Min, and J. G. Chi The Effect of Regular Salbutamol on Lung Function and Bronchial Responsiveness in Patients with Primary Ciliary Dyskinesia Chest, February 1, 2000; 117(2): 427 - 433. [Abstract] [Full Text] [PDF]

				J. M. Edelman, J. A. Turpin, E. A. Bronsky, J. Grossman, J. P. Kemp, A. F. Ghannam, P. T. DeLucca, G. J. Gormley, D. S. Pearlman, and for the Exercise Study Group* Oral Montelukast Compared with Inhaled Salmeterol To Prevent Exercise-Induced Bronchoconstriction: A Randomized, Double-Blind Trial Ann Intern Med, January 18, 2000; 132(2): 97 - 104. [Abstract] [Full Text] [PDF]

				Leukotriene-receptor antagonists and related compounds Can. Med. Assoc. J., November 1, 1999; 161(90111): s31 - 34. [Full Text]

				J. A. Nelson, L. Strauss, M. Skowronski, R. Ciufo, R. Novak, and E.R. McFadden Effect of Long-Term Salmeterol Treatment on Exercise-Induced Asthma N. Engl. J. Med., July 16, 1998; 339(3): 141 - 146. [Abstract] [Full Text] [PDF]

				J. A. Leff, W. W. Busse, D. Pearlman, E. A. Bronsky, J. Kemp, L. Hendeles, R. Dockhorn, S. Kundu, J. Zhang, B. C. Seidenberg, et al. Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction N. Engl. J. Med., July 16, 1998; 339(3): 147 - 152. [Abstract] [Full Text] [PDF]

				Using {beta}2-stimulants in asthma DTB, January 1, 1997; 35(1): 1 - 4. [Abstract] [Full Text] [PDF]

				P. M. O'Byrne and H. A.M. Kerstjens Inhaled {beta}2-Agonists in the Treatment of Asthma N. Engl. J. Med., September 19, 1996; 335(12): 886 - 888. [Full Text]